BioMarin, Sarah Cannon Research UK Expand PARP Inhibitor Trial Outside US | GenomeWeb

NEW YORK (GenomeWeb) – Sarah Cannon Research UK is enrolling patients for BioMarin's Phase III EMBARCA trial investigating BMN 673 as a treatment for BRCA-mutation positive hereditary breast cancer.

In a statement, Sarah Cannon Research UK said it had enrolled the first patient in the EMBARCA study outside of the US, "expanding the trial internationally." The aim of the Phase III study is to evaluate the safety and efficacy of the PARP inhibitor BMN 673.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.